Global Hepatitis Drugs Market – Drivers, Opportunities, Trends, and Forecasts: 2017–2023
Overview: Hepatitis is a medical condition where the liver is predominantly affected, which can also affect the digestive system and brain. There are three major types of hepatitis condition – HAV, HBV, and HCV. HCV is a major public health problem that attacks the liver and leads to inflammation. Certain drugs, toxins, heavy alcohol use, bacterial and viral infections can cause hepatitis infection. Hepatitis C infection can bring both acute and chronic hepatitis disease. Approximately, 80% of the patients get chronically infected with Hepatitis C disease. Hepatitis C Virus (HCV) spreads through the blood of an infected individual by the use of shared needles or supplies used to infuse drugs. Vaccines are available only for Hepatitis A and Hepatitis B viruses. Research into the development of a vaccine for Hepatitis C is under way.
Factors such as rise in injection drug users, increase in awareness, presence of unmet need, and anticipated launch of new drugs are expected to drive the market growth during the forecast period. The market is witnessing the emerging trend of pediatric combination vaccines, which protect against multiple causative agents and thereby reduce the costs gain in packaging and administering individual vaccines. The markets in India, Brazil, China, and Russia are also expected to grow at a rapid pace during the forecast period as the prevalence of hepatitis in these countries is high.
The major drivers of the hepatitis drugs market include the second generation DAAs of Olysio and Sovaldi. Second generation DAAs are more efficacious and have lesser adverse effects. Currently, the market players are developing IFN therapies for the treatment of Hepatitis C. These therapies are intended to be all-oral regimens. The HCV drugs segment comprised more than 84% of the total market share in 2016. A major focus in this segment is expected to drive the growth of the hepatitis drugs market in the future.
Market Analysis: The “Global Hepatitis Drugs Market” is estimated to witness a CAGR of 15.0% during the forecast period 2017–2023. The Hepatitis Drugs market is analyzed based on two segments – conditions and regions.
Regional Analysis: The regions covered in the report are the Americas, Europe, Asia Pacific, and Rest of the World (RoW). The Americas is set to be the leading region for the hepatitis drugs market growth followed by Europe. The Asia Pacific and RoW are set to be the emerging regions. Japan is set to be the most attractive destination and in Africa, the popularity and the usage of various HBV and HCV drugs are expected to increase in the coming years.
Therapeutic Application Analysis: The most common hepatitis being viral hepatitis can be caused by either of the five hepatotropic viruses, namely Hepatitis A, Hepatitis B, Hepatitis C, Hepatitis D, and Hepatitis E. The non-viral hepatitis can be caused by autoimmune diseases, alcohol, few of prescription medications, and toxic substances. Globally, the industry players are focusing significantly on R&D to gain approval for various clinical trials for future HBV and HCV drugs to be commercially available in the market. The advent of interferon-free combination regimens and DAAs is one of the major drivers for the global hepatitis drugs market, specifically for the HCV market. Moreover, various IFN-regimens are under development as all-oral regimens. These therapies are expected to attain higher SVR and cause lesser side effects than currently approved therapies. The market is also witnessing various mergers, acquisitions, and collaborations among the top players, which is defining the future of the Global Hepatitis Drugs market.
Key Players: Gilead Sciences Inc., Abbvie Inc., Johnson & Johnson, Merck & Co. Inc., GlaxoSmithKline plc, Vertex Pharmaceuticals Inc., Novartis AG, Hoffmann-La Roche Ltd., and other predominate & niche players.
Competitive Analysis: At present, the HCV drugs are dominating the Global Hepatitis Drugs market – but, a lot of new players are focusing on developing HBV drug molecules to gain future business opportunities. Especially, big players along with the collaboration with other SMBs for clinical trials of hepatitis molecules and compounds are coming with new commercial targeted drugs in the market and they are expecting a double-digit growth in the upcoming years. Significant investments in R&D in this market are expected to increase and collaborations, merger & acquisition activities are expected to continue.
Benefits: The report provides complete details about the usage and adoption rate of hepatitis drugs in various therapeutic verticals and regions. With that, key stakeholders can know about the major trends, drivers, investments, vertical player’s initiatives, and government initiatives towards the hepatitis drugs adoption in the upcoming years along with the details of commercial drugs available in the market. Moreover, the report provides details about the major challenges that are going to impact on the market growth. Additionally, the report gives the complete details about the key business opportunities to key stakeholders to expand their business and capture the revenue in the specific verticals to analyze before investing or expanding the business in this market.
Factors such as rise in injection drug users, increase in awareness, presence of unmet need, and anticipated launch of new drugs are expected to drive the market growth during the forecast period. The market is witnessing the emerging trend of pediatric combination vaccines, which protect against multiple causative agents and thereby reduce the costs gain in packaging and administering individual vaccines. The markets in India, Brazil, China, and Russia are also expected to grow at a rapid pace during the forecast period as the prevalence of hepatitis in these countries is high.
The major drivers of the hepatitis drugs market include the second generation DAAs of Olysio and Sovaldi. Second generation DAAs are more efficacious and have lesser adverse effects. Currently, the market players are developing IFN therapies for the treatment of Hepatitis C. These therapies are intended to be all-oral regimens. The HCV drugs segment comprised more than 84% of the total market share in 2016. A major focus in this segment is expected to drive the growth of the hepatitis drugs market in the future.
Market Analysis: The “Global Hepatitis Drugs Market” is estimated to witness a CAGR of 15.0% during the forecast period 2017–2023. The Hepatitis Drugs market is analyzed based on two segments – conditions and regions.
Regional Analysis: The regions covered in the report are the Americas, Europe, Asia Pacific, and Rest of the World (RoW). The Americas is set to be the leading region for the hepatitis drugs market growth followed by Europe. The Asia Pacific and RoW are set to be the emerging regions. Japan is set to be the most attractive destination and in Africa, the popularity and the usage of various HBV and HCV drugs are expected to increase in the coming years.
Therapeutic Application Analysis: The most common hepatitis being viral hepatitis can be caused by either of the five hepatotropic viruses, namely Hepatitis A, Hepatitis B, Hepatitis C, Hepatitis D, and Hepatitis E. The non-viral hepatitis can be caused by autoimmune diseases, alcohol, few of prescription medications, and toxic substances. Globally, the industry players are focusing significantly on R&D to gain approval for various clinical trials for future HBV and HCV drugs to be commercially available in the market. The advent of interferon-free combination regimens and DAAs is one of the major drivers for the global hepatitis drugs market, specifically for the HCV market. Moreover, various IFN-regimens are under development as all-oral regimens. These therapies are expected to attain higher SVR and cause lesser side effects than currently approved therapies. The market is also witnessing various mergers, acquisitions, and collaborations among the top players, which is defining the future of the Global Hepatitis Drugs market.
Key Players: Gilead Sciences Inc., Abbvie Inc., Johnson & Johnson, Merck & Co. Inc., GlaxoSmithKline plc, Vertex Pharmaceuticals Inc., Novartis AG, Hoffmann-La Roche Ltd., and other predominate & niche players.
Competitive Analysis: At present, the HCV drugs are dominating the Global Hepatitis Drugs market – but, a lot of new players are focusing on developing HBV drug molecules to gain future business opportunities. Especially, big players along with the collaboration with other SMBs for clinical trials of hepatitis molecules and compounds are coming with new commercial targeted drugs in the market and they are expecting a double-digit growth in the upcoming years. Significant investments in R&D in this market are expected to increase and collaborations, merger & acquisition activities are expected to continue.
Benefits: The report provides complete details about the usage and adoption rate of hepatitis drugs in various therapeutic verticals and regions. With that, key stakeholders can know about the major trends, drivers, investments, vertical player’s initiatives, and government initiatives towards the hepatitis drugs adoption in the upcoming years along with the details of commercial drugs available in the market. Moreover, the report provides details about the major challenges that are going to impact on the market growth. Additionally, the report gives the complete details about the key business opportunities to key stakeholders to expand their business and capture the revenue in the specific verticals to analyze before investing or expanding the business in this market.
1 INDUSTRY OUTLOOK
1.1 Industry Overview
1.2 Industry Trends
1.3 Pest Analysis
2 REPORT OUTLINE
2.1 Report Scope
2.2 Report Summary
2.3 Research Methodology
2.4 Report Assumptions
3 MARKET SNAPSHOT
3.1 Total Addressable Market (TAM)
3.2 Disease Overview
3.2.1 Hepatitis A
3.2.1.1 Epidemiology
3.2.1.2 Therapy
3.2.2 Hepatitis B
3.2.2.1 Epidemiology
3.2.2.2 Therapy
3.2.3 Hepatitis C
3.2.3.1 Epidemiology
3.2.3.2 Therapy
3.2.4 Hepatitis D
3.2.5 Hepatitis E
3.3 Disease Transmission
3.4 Related Markets
4 MARKET OUTLOOK
4.1 Overview
4.2 Regulatory Bodies & Standards
4.3 Porter 5 (Five) Forces
5 MARKET CHARACTERISTICS
5.1 Evolution
5.2 ROADMAP
5.3 Market Dynamics
5.3.1 Drivers
5.3.1.1 Increasing Demand of Hepatitis Drugs
5.3.1.2 Focus on Advanced DAAs
5.3.1.3 Introduction of IFN-free Therapies
5.3.1.4 Growth of Injection Drug Users
5.3.2 Restraints
5.3.2.1 Long Approval Process and Stringent Regulations
5.3.2.2 Side Effects of Hepatitis Drugs
5.3.2.3 Increase in the Number of Generic Drugs
5.3.2.4 Increasing Market Competition
5.3.3 Opportunities
5.3.3.1 Significant Increase in Mergers and Acquisitions
5.3.3.2 Emergence of Combination Drugs
5.3.3.3 Preventive Healthcare
5.3.3.4 Focus of Companies on Emerging Market
5.3.4 DRO – Impact Analysis
6 TRENDS, ROADMAP AND PROJECTS
6.1 Market Trends & Impact
6.2 Technology Roadmap
7 TYPES: MARKET SIZE & ANALYSIS
7.1 Overview
7.2 Hepatitis A Segment
7.3 Hepatitis B Segment
7.4 Hepatitis C Segment
8 TRENDING HEPATITIS DRUGS
8.1 Overview
8.1.1 VEMLIDY
8.1.2 EPCLUSA
8.1.3 SOVALDI
8.1.4 INCIVEK
8.1.5 OLYSIO
8.1.6 VICTRELIS
8.1.7 VIREAD
8.1.8 HEPSERA
8.1.9 BARACLUDE
8.1.10 TYZEKA
8.1.11 INTRON A
8.1.12 PEGASYS
8.1.13 PEGINTRON
8.1.14 ROFERON-A
8.1.15 VIRAFERONPEG
8.1.16 REBETOL
9 REGIONS: MARKET SIZE & ANALYSIS
9.1 OVERVIEW
9.1.1.1 Global Hepatitis Drugs Market by Geographical Segmentation
10 VENDOR SCENARIO
10.1 Market Share Ranking 2016
10.1.1 GILEAD SCIENCES INC.
10.1.1.1 Sovaldi (sofosbuvir)
10.1.1.2 Harvoni (ledipasvir and sofosbuvir)
10.1.1.3 Viread (tenofovir disoproxil fumarate)
10.1.1.4 Hepsera (adefovir dipivoxil)
10.1.2 ABBVIE INC.
10.1.2.1 Viekira Pak (ombitasvir, paritaprevir, ritonavir and dasabuvir)
10.1.3 JOHNSON & JOHNSON
10.1.3.1 Olysio (simeprevir)
10.1.3.2 Incivo(telaprevir)
10.1.4 MERCK & CO. INC.
10.1.4.1 Zepatier (elbasvir and grazoprevir)
10.1.4.2 Victrelis (boceprevir)
10.1.4.3 Peg-Intron (peginterferon alfa-2b)
10.1.4.4 Rebetol (ribavirin)
10.1.4.5 Intron A (interferon alfa-2b, recombinant)
10.1.5 GLAXOSMITHKLINE PLC
10.1.5.1 Pediarix Vaccine
10.1.5.2 Twinrix
10.1.5.3 Havrix
10.1.5.4 Epivir (lamivudine)
10.1.6 VERTEX PHARMACEUTICALS INC.
10.1.6.1 Incivek (telaprevir)
10.1.7 NOVARTIS AG
10.1.7.1 Tyzeka (telbivudine)
10.1.8 HOFFMANN-LA ROCHE LTD.
10.1.8.1 Pegasys (peginterferon alfa-2a)
11 VENDOR PROFILES
11.1.1 Merck & Co. Inc.
11.1.1.1 Overview
11.1.1.2 Business unit
11.1.1.3 Geographic revenue
11.1.1.4 Recent developments
11.1.1.5 SWOT analysis
11.1.1.6 Business strategies
11.1.2 Hoffmann-La Roche Ltd.
11.1.2.1 Overview
11.1.2.2 Business Unit
11.1.2.3 Geographic revenue
11.1.2.4 Recent developments
11.1.2.5 SWOT analysis
11.1.2.6 Business strategies
11.1.3 Gilead Sciences
11.1.3.1 Overview
11.1.3.2 Business Unit
11.1.3.3 Geographic revenue
11.1.3.4 Recent developments
11.1.3.5 SWOT analysis
11.1.3.6 Business strategies
11.1.4 Novartis AG
11.1.4.1 Overview
11.1.4.2 Business Unit
11.1.4.3 Geographic revenue
11.1.4.4 Recent developments
11.1.4.5 SWOT analysis
11.1.4.6 Business strategies
11.1.5 GlaxoSmithKline plc
11.1.5.1 Overview
11.1.5.2 Business Unit
11.1.5.3 Geographic revenue
11.1.5.4 Recent developments
11.1.5.5 SWOT analysis
11.1.5.6 Business strategies
12 GLOBAL GENERALIST
12.1 Vertex Pharmaceuticals Inc.
12.1.1 Overview
12.1.1.1 Recent developments
12.1.2 Vertex Pharmaceuticals Inc. in 2015
12.2 Johnson & Johnson
12.2.1 Overview
12.2.1.1 Recent developments
12.2.2 Johnson & Johnson in 2015
13 MARKET LANDSCAPE
13.1 Market Landscape
13.1.1 Mergers & Acquisitions (M&A)
Annexure
? Acronyms
Table 1 MAJOR HEPATITIS A DRUGS
Table 2 MAJOR HEPATTIS B DRUGS
Table 3 MAJOR HEPATITIS C DRUGS
Table 4 DISEASE TRANSMISSIONS OF DIFFERENT TYPES OF HEPATITIS
Table 5 GLOBAL HEPATITIS DRUGS MARKET REVENUE BY TYPE, 2016-2023 ($BILLION)
Table 6 TRENDING HEPATITIS DRUGS, 2014-2016 ($MILLION)
Table 7 MERCK & CO. INC.: RECENT DEVELOPMENTS
Table 8 HOFFMANN-LA ROCHE LTD.: RECENT DEVELOPMENTS
Table 9 GILEAD SCIENCES: KEY MEDICINES/PRODUCTS
Table 10 GILEAD SCIENCES: PIPELINE PRODUCTS
Table 11 GILEAD SCIENCES: RECENT DEVELOPMENTS
Table 12 NOVARTIS AG: RECENT DEVELOPMENTS
Table 13 GLAXOSMITHKLINE PLC: RECENT DEVELOPMENTS
Table 14 VERTEX PHARMACEUTICALS INC.: RECENT DEVELOPMENTS
Table 15 JOHNSON & JOHNSON: RECENT DEVELOPMENTS
Table 16 MERGER & ACQUISITION, 2014–2015
Chart 1 PEST ANALYSIS OF HEPATITIS DRUGS MARKET
Chart 2 RESEARCH METHODOLOGY OF GLOBAL HEPATITIS DRUGS MARKET
Chart 3 GLOBAL HEPATITIS DRUGS MARKET REVENUE, 2016-2023 ($BILLION)
Chart 4 PORTERS 5 FORCES ON GLOBAL HEPATITS DRUGS MARKET
Chart 5 EVOLUTION OF HEPATITIS DRUGS
Chart 6 REGIMEN ROADMAP OF HEPATITIS C
Chart 7 MARKET DYNAMICS – DRIVERS, RESTRAINTS & OPPORTUNITIES
Chart 8 DRO - IMPACT ANALYSIS OF HEPATITIS DRUGS MARKET
Chart 9 TECHNOLOGY ROADMAP FOR HEPATITIS DRUGS MARKET
Chart 10 HEPATITIS DRUGS MARKET BY TYPES
Chart 11 GLOBAL HEPATITIS DRUGS MARKET SHARE BY TYPES 2016
Chart 12 GLOBAL HEPATITIS DRUGS MARKET REVENUE IN HEPATITIS A SEGMENT, 2016-2023 ($BILLION)
Chart 13 GLOBAL HEPATITIS DRUGS MARKET REVENUE IN HEPATITIS B SEGMENT, 2016-2023 ($BILLION)
Chart 14 GLOBAL HEPATITIS DRUGS MARKET REVENUE IN HEPATITIS C SEGMENT, 2016-2023 ($BILLION)
Chart 15 GEOGRAPHIC REVENUE IN 2015 (%)
Chart 16 MERCK & CO. INC.: OVERVIEW SNAPSHOT
Chart 17 MERCK & CO. INC.: BUSINESS UNITS
Chart 18 GE: GEOGRAPHIC REVENUE
Chart 19 MERCK & CO. INC.: SWOT ANALYSIS
Chart 20 HOFFMANN-LA ROCHE LTD.: OVERVIEW SNAPSHOT
Chart 21 HOFFMANN-LA ROCHE LTD.: BUSINESS UNITS
Chart 22 HOFFMANN-LA ROCHE LTD.: GEOGRAPHIC REVENUE
Chart 23 HOFFMANN-LA ROCHE LTD.: SWOT ANALYSIS
Chart 24 GILEAD SCIENCES: OVERVIEW SNAPSHOT
Chart 25 GILEAD SCIENCES: BUSINESS UNITS
Chart 26 GILEAD SCIENCES: GEOGRAPHIC REVENUE
Chart 27 GILEAD SCIENCES: SWOT ANALYSIS
Chart 28 NOVARTIS AG: OVERVIEW SNAPSHOT
Chart 29 NOVARTIS AG: BUSINESS UNITS
Chart 30 NOVARTIS AG: GEOGRAPHIC REVENUE
Chart 31 NOVARTIS AG: SWOT ANALYSIS
Chart 32 GLAXOSMITHKLINE PLC: OVERVIEW SNAPSHOT
Chart 33 GLAXOSMITHKLINE PLC: BUSINESS UNITS
Chart 34 GLAXOSMITHKLINE PLC: GEOGRAPHIC REVENUE
Chart 35 GLAXOSMITHKLINE PLC: SWOT ANALYSIS
Chart 36 VERTEX PHARMACEUTICALS INC.: OVERVIEW SNAPSHOT
Chart 37 JOHNSON & JOHNSON: OVERVIEW SNAPSHOT
1.1 Industry Overview
1.2 Industry Trends
1.3 Pest Analysis
2 REPORT OUTLINE
2.1 Report Scope
2.2 Report Summary
2.3 Research Methodology
2.4 Report Assumptions
3 MARKET SNAPSHOT
3.1 Total Addressable Market (TAM)
3.2 Disease Overview
3.2.1 Hepatitis A
3.2.1.1 Epidemiology
3.2.1.2 Therapy
3.2.2 Hepatitis B
3.2.2.1 Epidemiology
3.2.2.2 Therapy
3.2.3 Hepatitis C
3.2.3.1 Epidemiology
3.2.3.2 Therapy
3.2.4 Hepatitis D
3.2.5 Hepatitis E
3.3 Disease Transmission
3.4 Related Markets
4 MARKET OUTLOOK
4.1 Overview
4.2 Regulatory Bodies & Standards
4.3 Porter 5 (Five) Forces
5 MARKET CHARACTERISTICS
5.1 Evolution
5.2 ROADMAP
5.3 Market Dynamics
5.3.1 Drivers
5.3.1.1 Increasing Demand of Hepatitis Drugs
5.3.1.2 Focus on Advanced DAAs
5.3.1.3 Introduction of IFN-free Therapies
5.3.1.4 Growth of Injection Drug Users
5.3.2 Restraints
5.3.2.1 Long Approval Process and Stringent Regulations
5.3.2.2 Side Effects of Hepatitis Drugs
5.3.2.3 Increase in the Number of Generic Drugs
5.3.2.4 Increasing Market Competition
5.3.3 Opportunities
5.3.3.1 Significant Increase in Mergers and Acquisitions
5.3.3.2 Emergence of Combination Drugs
5.3.3.3 Preventive Healthcare
5.3.3.4 Focus of Companies on Emerging Market
5.3.4 DRO – Impact Analysis
6 TRENDS, ROADMAP AND PROJECTS
6.1 Market Trends & Impact
6.2 Technology Roadmap
7 TYPES: MARKET SIZE & ANALYSIS
7.1 Overview
7.2 Hepatitis A Segment
7.3 Hepatitis B Segment
7.4 Hepatitis C Segment
8 TRENDING HEPATITIS DRUGS
8.1 Overview
8.1.1 VEMLIDY
8.1.2 EPCLUSA
8.1.3 SOVALDI
8.1.4 INCIVEK
8.1.5 OLYSIO
8.1.6 VICTRELIS
8.1.7 VIREAD
8.1.8 HEPSERA
8.1.9 BARACLUDE
8.1.10 TYZEKA
8.1.11 INTRON A
8.1.12 PEGASYS
8.1.13 PEGINTRON
8.1.14 ROFERON-A
8.1.15 VIRAFERONPEG
8.1.16 REBETOL
9 REGIONS: MARKET SIZE & ANALYSIS
9.1 OVERVIEW
9.1.1.1 Global Hepatitis Drugs Market by Geographical Segmentation
10 VENDOR SCENARIO
10.1 Market Share Ranking 2016
10.1.1 GILEAD SCIENCES INC.
10.1.1.1 Sovaldi (sofosbuvir)
10.1.1.2 Harvoni (ledipasvir and sofosbuvir)
10.1.1.3 Viread (tenofovir disoproxil fumarate)
10.1.1.4 Hepsera (adefovir dipivoxil)
10.1.2 ABBVIE INC.
10.1.2.1 Viekira Pak (ombitasvir, paritaprevir, ritonavir and dasabuvir)
10.1.3 JOHNSON & JOHNSON
10.1.3.1 Olysio (simeprevir)
10.1.3.2 Incivo(telaprevir)
10.1.4 MERCK & CO. INC.
10.1.4.1 Zepatier (elbasvir and grazoprevir)
10.1.4.2 Victrelis (boceprevir)
10.1.4.3 Peg-Intron (peginterferon alfa-2b)
10.1.4.4 Rebetol (ribavirin)
10.1.4.5 Intron A (interferon alfa-2b, recombinant)
10.1.5 GLAXOSMITHKLINE PLC
10.1.5.1 Pediarix Vaccine
10.1.5.2 Twinrix
10.1.5.3 Havrix
10.1.5.4 Epivir (lamivudine)
10.1.6 VERTEX PHARMACEUTICALS INC.
10.1.6.1 Incivek (telaprevir)
10.1.7 NOVARTIS AG
10.1.7.1 Tyzeka (telbivudine)
10.1.8 HOFFMANN-LA ROCHE LTD.
10.1.8.1 Pegasys (peginterferon alfa-2a)
11 VENDOR PROFILES
11.1.1 Merck & Co. Inc.
11.1.1.1 Overview
11.1.1.2 Business unit
11.1.1.3 Geographic revenue
11.1.1.4 Recent developments
11.1.1.5 SWOT analysis
11.1.1.6 Business strategies
11.1.2 Hoffmann-La Roche Ltd.
11.1.2.1 Overview
11.1.2.2 Business Unit
11.1.2.3 Geographic revenue
11.1.2.4 Recent developments
11.1.2.5 SWOT analysis
11.1.2.6 Business strategies
11.1.3 Gilead Sciences
11.1.3.1 Overview
11.1.3.2 Business Unit
11.1.3.3 Geographic revenue
11.1.3.4 Recent developments
11.1.3.5 SWOT analysis
11.1.3.6 Business strategies
11.1.4 Novartis AG
11.1.4.1 Overview
11.1.4.2 Business Unit
11.1.4.3 Geographic revenue
11.1.4.4 Recent developments
11.1.4.5 SWOT analysis
11.1.4.6 Business strategies
11.1.5 GlaxoSmithKline plc
11.1.5.1 Overview
11.1.5.2 Business Unit
11.1.5.3 Geographic revenue
11.1.5.4 Recent developments
11.1.5.5 SWOT analysis
11.1.5.6 Business strategies
12 GLOBAL GENERALIST
12.1 Vertex Pharmaceuticals Inc.
12.1.1 Overview
12.1.1.1 Recent developments
12.1.2 Vertex Pharmaceuticals Inc. in 2015
12.2 Johnson & Johnson
12.2.1 Overview
12.2.1.1 Recent developments
12.2.2 Johnson & Johnson in 2015
13 MARKET LANDSCAPE
13.1 Market Landscape
13.1.1 Mergers & Acquisitions (M&A)
Annexure
? Acronyms
Table 1 MAJOR HEPATITIS A DRUGS
Table 2 MAJOR HEPATTIS B DRUGS
Table 3 MAJOR HEPATITIS C DRUGS
Table 4 DISEASE TRANSMISSIONS OF DIFFERENT TYPES OF HEPATITIS
Table 5 GLOBAL HEPATITIS DRUGS MARKET REVENUE BY TYPE, 2016-2023 ($BILLION)
Table 6 TRENDING HEPATITIS DRUGS, 2014-2016 ($MILLION)
Table 7 MERCK & CO. INC.: RECENT DEVELOPMENTS
Table 8 HOFFMANN-LA ROCHE LTD.: RECENT DEVELOPMENTS
Table 9 GILEAD SCIENCES: KEY MEDICINES/PRODUCTS
Table 10 GILEAD SCIENCES: PIPELINE PRODUCTS
Table 11 GILEAD SCIENCES: RECENT DEVELOPMENTS
Table 12 NOVARTIS AG: RECENT DEVELOPMENTS
Table 13 GLAXOSMITHKLINE PLC: RECENT DEVELOPMENTS
Table 14 VERTEX PHARMACEUTICALS INC.: RECENT DEVELOPMENTS
Table 15 JOHNSON & JOHNSON: RECENT DEVELOPMENTS
Table 16 MERGER & ACQUISITION, 2014–2015
Chart 1 PEST ANALYSIS OF HEPATITIS DRUGS MARKET
Chart 2 RESEARCH METHODOLOGY OF GLOBAL HEPATITIS DRUGS MARKET
Chart 3 GLOBAL HEPATITIS DRUGS MARKET REVENUE, 2016-2023 ($BILLION)
Chart 4 PORTERS 5 FORCES ON GLOBAL HEPATITS DRUGS MARKET
Chart 5 EVOLUTION OF HEPATITIS DRUGS
Chart 6 REGIMEN ROADMAP OF HEPATITIS C
Chart 7 MARKET DYNAMICS – DRIVERS, RESTRAINTS & OPPORTUNITIES
Chart 8 DRO - IMPACT ANALYSIS OF HEPATITIS DRUGS MARKET
Chart 9 TECHNOLOGY ROADMAP FOR HEPATITIS DRUGS MARKET
Chart 10 HEPATITIS DRUGS MARKET BY TYPES
Chart 11 GLOBAL HEPATITIS DRUGS MARKET SHARE BY TYPES 2016
Chart 12 GLOBAL HEPATITIS DRUGS MARKET REVENUE IN HEPATITIS A SEGMENT, 2016-2023 ($BILLION)
Chart 13 GLOBAL HEPATITIS DRUGS MARKET REVENUE IN HEPATITIS B SEGMENT, 2016-2023 ($BILLION)
Chart 14 GLOBAL HEPATITIS DRUGS MARKET REVENUE IN HEPATITIS C SEGMENT, 2016-2023 ($BILLION)
Chart 15 GEOGRAPHIC REVENUE IN 2015 (%)
Chart 16 MERCK & CO. INC.: OVERVIEW SNAPSHOT
Chart 17 MERCK & CO. INC.: BUSINESS UNITS
Chart 18 GE: GEOGRAPHIC REVENUE
Chart 19 MERCK & CO. INC.: SWOT ANALYSIS
Chart 20 HOFFMANN-LA ROCHE LTD.: OVERVIEW SNAPSHOT
Chart 21 HOFFMANN-LA ROCHE LTD.: BUSINESS UNITS
Chart 22 HOFFMANN-LA ROCHE LTD.: GEOGRAPHIC REVENUE
Chart 23 HOFFMANN-LA ROCHE LTD.: SWOT ANALYSIS
Chart 24 GILEAD SCIENCES: OVERVIEW SNAPSHOT
Chart 25 GILEAD SCIENCES: BUSINESS UNITS
Chart 26 GILEAD SCIENCES: GEOGRAPHIC REVENUE
Chart 27 GILEAD SCIENCES: SWOT ANALYSIS
Chart 28 NOVARTIS AG: OVERVIEW SNAPSHOT
Chart 29 NOVARTIS AG: BUSINESS UNITS
Chart 30 NOVARTIS AG: GEOGRAPHIC REVENUE
Chart 31 NOVARTIS AG: SWOT ANALYSIS
Chart 32 GLAXOSMITHKLINE PLC: OVERVIEW SNAPSHOT
Chart 33 GLAXOSMITHKLINE PLC: BUSINESS UNITS
Chart 34 GLAXOSMITHKLINE PLC: GEOGRAPHIC REVENUE
Chart 35 GLAXOSMITHKLINE PLC: SWOT ANALYSIS
Chart 36 VERTEX PHARMACEUTICALS INC.: OVERVIEW SNAPSHOT
Chart 37 JOHNSON & JOHNSON: OVERVIEW SNAPSHOT
